{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1250"},{"groupId":"OG001","value":"1250"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"To determine the Recommended Phase 2 Dose of SQ3370","groups":[{"description":"Participants will receive 10 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.\n\nSQ3370: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin","id":"OG000","title":"Dose Escalation Cohort (10 mL SQL70)"},{"description":"Participants will receive 20 mL of SQL70 biopolymer injected intratumorally on Day 1 of each 21-day cycle into a single lesion and then receive escalating doses of SQP33 protodrug administered IV from Day 1 through Day 5 (5 doses) of each 21-day cycle.\n\nSQ3370: SQ3370 consists of 2 components: SQL70, a protodrug-activating biopolymer, and SQP33, a protodrug of Doxorubicin","id":"OG001","title":"Dose Escalation Cohort (20 mL SQL70)"}],"paramType":"NUMBER","populationDescription":"Dose escalation participants","reportingStatus":"POSTED","timeFrame":"From start of treatment to approximately 12 weeks","title":"Phase 1 Cohorts","type":"PRIMARY","unitOfMeasure":"mg/m2 per cycle"}